Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04069169
Other study ID # H18-03103
Secondary ID
Status Completed
Phase Phase 3
First received
Last updated
Start date December 18, 2019
Est. completion date May 10, 2024

Study information

Verified date May 2024
Source University of British Columbia
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Surgical correction of scoliosis in children is a long procedure, with an equivalently long recovery time, that is commonly performed at BC Children's Hospital. Treating pain immediately after the procedure is a priority for children during recovery. Morphine is one medication that can be used to manage post-operative pain, but unfortunately, its use is accompanied by a number of side effects which can affect recovery. These include nausea, vomiting, pruritus, sedation, dysphoria, respiratory depression, constipation, ileus, and urinary retention. In order to control pain and reduce morphine consumption, intravenous lidocaine is being investigated. This therapy has been beneficial in adult populations undergoing abdominal surgery and has been associated with decreased post-operative pain, decrease use of opioids including morphine, and ileus. These all contribute to shorter lengths of stay in the hospital and better recovery in the adult population. Intravenous lidocaine is used by some anesthesiologists at BC Children's Hospital to manage post-operative pain in children receiving surgical correction for scoliosis, but this is not a standard of practice. We now propose to conduct a double-blind randomized controlled trial to determine if intravenous lidocaine, infused from start of anesthesia up to 48 hours post-operatively, will reduce morphine use and improve post-operative pain in the pediatric population.


Description:

Objectives: The primary objective of this study is to determine if perioperative IV lidocaine therapy (P-IVLT) reduces 48-hour post-operative morphine utilization compared with a control, in adolescents undergoing PSIF. Secondary objectives of this study are to determine the effect of P-IVLT on self-reported pain scores, time to documented first stand, time to first walk of greater than 15 steps, and length of hospital stay (LOS). Research Methods: This will be a placebo-controlled, double-blind randomized control trial (RCT) comparing 48-hour postoperative morphine utilization among adolescents undergoing PSIF who have been randomly assigned to one of two groups: Intervention group (A) will receive P-IVLT in addition to the standard multimodal analgesia. P-IVLT will consist of 1 mg/kg bolus at start of anesthesia (T0), followed by 2 mg·kg-1·hr-1 infusion for 8 hours (T1), then continued at 1 mg·kg-1·hr-1 infusion thereafter and postoperatively until T0 + 48 hours (T2). Control group (B) will receive a placebo (0.9% sodium chloride also known as normal saline), made to mimic the intervention protocol above, in addition to the standard multimodal analgesia.


Recruitment information / eligibility

Status Completed
Enrollment 48
Est. completion date May 10, 2024
Est. primary completion date May 10, 2024
Accepts healthy volunteers No
Gender All
Age group 10 Years to 19 Years
Eligibility Inclusion Criteria: - ASA I-III - Diagnosed with Idiopathic scoliosis - Undergoing single-stage posterior spinal instrumentation and fusion Exclusion Criteria: - Thorascopic tethering procedure - Two-stage procedure - Abnormal developmental profile - Congenital/neuromuscular scoliosis - Requiring PICU admission - Known allergy to lidocaine - Known cardiac, renal or liver disease or dysfunction - Pre-existing pain complaints, i.e. on regular analgesic medications - Current psychiatric diagnosis, e.g. anxiety, depression, eating disorder, defined according to DSM criteria. - Requiring non-standard post-op pain management - Any history of seizures - Unplanned staged procedure - Weight < 5th centile or > 85th centile for age - Porphyria

Study Design


Intervention

Drug:
Lidocaine
Intervention group (A) will receive P-IVLT in addition to the standard multimodal analgesia. P-IVLT will consist of 1 mg/kg bolus at start of anesthesia (T0), followed by 2 mg·kg-1·hr-1 infusion for 8 hours (T1), then continued at 1 mg·kg-1·hr-1 infusion thereafter and postoperatively until T0 + 48 hours (T2).
Saline Solution
Control group (B) will receive a placebo (0.9% sodium chloride also known as normal saline), made to mimic the intervention protocol described above, in addition to the standard multimodal analgesia.

Locations

Country Name City State
Canada BC Children's Hospital - Department of Anesthesia Vancouver British Columbia

Sponsors (1)

Lead Sponsor Collaborator
University of British Columbia

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Total morphine utilization Documented from acute pain service charts (mg/kg) 48 hours post-operatively
Secondary Total morphine utilization Documented from acute pain service charts (mg/kg) 12, 24, 36 hours post-operatively
Secondary Postoperative pain Pain scores measured every 4 hours by nursing staff from emergence in the anesthetic care unit through 48 hours post-operatively
Secondary Mobililzation Time from anesthesia induction to first walk of greater than 15 steps (hours) through hospital stay, an average of 5 days
Secondary Urinary incontinence Time from anesthesia induction to urinary catheter removal (hours) through hospital stay, an average of 5 days
Secondary Postoperative pain (II) Time from anesthesia induction to termination of morphine (hours) through study completion, 48 hours post-operatively
Secondary Recovery Time from anesthesia induction to discharge from hospital (days) through hospital stay, an average of 5 days
See also
  Status Clinical Trial Phase
Recruiting NCT05888038 - Virtual Reality's Effect on Decreasing Pain and Subsequent Opioid Use in Pediatric Patients in the Post-Operative Period Following Scoliosis Repair N/A
Recruiting NCT03582917 - The Role of VitD in Rehabilitation of Idiopathic Adolescent Scoliosis Phase 2
Recruiting NCT03904914 - Thumb Ossification Composite Index (TOCI) to Predict Skeletal Maturity and Curve Progression in AIS
Recruiting NCT04601363 - Personalized Spine Study Group (PSSG) Registry
Recruiting NCT06086431 - Dexamethasone vs. Dexmedetomidine for ESPB in Pain Management After Pediatric Idiopathic Scoliosis Surgery Phase 4
Completed NCT05185050 - Prevalence of Myofascial Pain Syndrome in Adolescent Idiopathic Scoliosis
Completed NCT04215497 - Effect of PSSE on Spine Reposition Sensation in Scoliosis N/A
Completed NCT05227638 - Investigation of the Efficacy of PNF and Schroth Treatment N/A
Active, not recruiting NCT04899297 - Quality of Life in Parents of Adolescents With Spinal Deformities: Development of a New Questionnaire.
Recruiting NCT06093477 - Studying Melatonin and Recovery in Teens N/A
Completed NCT05479695 - The Effect Insoles on Functional Capacity With Adolescent Idiopathic Scoliosis Using Spinal Orthosis N/A
Not yet recruiting NCT06429202 - The Relationship Between Body Perception and Self-Esteem Level and Quality of Life in Adolescent Idiopathic Scoliosis
Recruiting NCT06417944 - The Effect of Three-dimensional Exercise (Schroth Exercise) on Diaphragm Thickness in Adolescent Idiopathic Scoliosis Patients
Recruiting NCT05145725 - Instrumented POsterolateral Arthrodesis for Adolescent Idiopathic Scoliosis
Active, not recruiting NCT04226209 - Effect of PSSE on Plantar Pressure Distribution and Balance in Scoliosis N/A
Completed NCT04822935 - Postoperative Pain in Adolescent Idiopathic Scoliosis Surgery N/A
Not yet recruiting NCT06242821 - Back Pain Management in AIS: Yoga vs Physical Therapy N/A
Completed NCT03968146 - Erector Spinae Plane Block in Scoliotic Adolescents Phase 2
Completed NCT03183479 - The Effects of Fibrinogen Concentrate Infusion on Blood Loss and Allogeneic Blood Conservation in Scoliosis Surgery Phase 4
Not yet recruiting NCT06416579 - Comparison of the Efficiency of Schroth Method and Virtual Reality Exercises in Individuals With AIS N/A